世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

NA試験室開発検査（LDTs）市場 - 2030年までの産業動向と予測


NA Laboratory-Developed Tests (LDTs) Market - Industry Trends and Forecast to 2030

北米の臨床検査室開発試験（LDTs）市場は、2022年の69億1,100万ドルから2030年には176億8,085万ドルに達し、2023年から2030年の予測期間中に年平均成長率12.5％で成長すると予測される。 市場区分 北米の臨床... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年6月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		275 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

北米の臨床検査室開発試験（LDTs）市場は、2022年の69億1,100万ドルから2030年には176億8,085万ドルに達し、2023年から2030年の予測期間中に年平均成長率12.5％で成長すると予測される。

市場区分
北米の臨床検査室開発検査（LDTs）市場：検査タイプ別（臨床化学・免疫学、クリティカルケア、血液学、分子診断学、微生物学、その他の検査）、製品タイプ別（消耗品、分析装置・機器、アクセサリー）、サンプルタイプ別（血液、尿、組織、脳脊髄液（CSF）、その他）、治療領域別（感染症、遺伝子疾患、癌/癌、その他）、性別（男性、女性）、年齢層（老年、成人、小児）、エンドユーザー（病院ラボ、単独ラボ、診断チェーン、学術機関、臨床研究機関、専門診断センター、その他）、流通チャネル（直販、小売販売、第三者流通、その他）、国（U.S.,産業動向と2030年までの予測

北米の臨床検査開発試験（LDTs）市場ダイナミクスの概要

促進要因

- 個別化医薬品の需要の増加
- 分子診断学の進歩

阻害要因

- LDTの厳しい品質管理と標準化
機会

- 精密医療と標的治療の需要の増加
市場プレーヤー
北米の臨床検査開発試験（LDTs）市場で事業を展開する主な市場プレーヤーを以下に挙げる：
- F.ホフマン・ラ・ロシュ社
- bioMérieux, Inc.
- シスメックス・コーポレーション
- バイオメリカ社
- バイオ・ラッド・ラボラトリーズ
- アボット
- シーメンス・メディカル・ソリューションズUSA
- クエスト・ダイアグノスティックス
- QIAGEN
- ユーロフィンズサイエンティフィック
- バイオデシックス
- ホロジック社
- ガーダントヘルス
- OPKOヘルス社
- BD
- ベックマン・コールター社
- ネオジェノミクス・ラボラトリーズ
- シージーン社
- アンブリージェネティクス
- BGI
- 23andMe社
- アドメラヘルス
- アジェンディア



ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 65
1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF THE NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 65
1.4 CURRENCY AND PRICING 67
1.5 LIMITATIONS 67
1.6 MARKETS COVERED 67
2 MARKET SEGMENTATION 72
2.1 MARKETS COVERED 72
2.2 GEOGRAPHICAL SCOPE 73
2.3 YEARS CONSIDERED FOR THE STUDY 74
2.4 DBMR TRIPOD DATA VALIDATION MODEL 75
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.6 MULTIVARIATE MODELLING 79
2.7 TEST TYPE SEGMENT LIFELINE CURVE 79
2.8 MARKET END USER COVERAGE GRID 80
2.9 DBMR MARKET POSITION GRID 81
2.10 VENDOR SHARE ANALYSIS 82
2.11 SECONDARY SOURCES 83
2.12 ASSUMPTIONS 83
3 EXECUTIVE SUMMARY 84
4 PREMIUM INSIGHTS 87
4.1 PESTEL ANALYSIS 88
4.2 PORTER'S FIVE FORCES MODEL 89
5 INDUSTRY INSIGHTS 90
6 NUMBER OF LABS 92
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 92
6.2 NUMBER OF LABS IN EUROPE 92
7 REGULATIONS OF THE NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 94
7.1 U.S. 94
8 MARKET OVERVIEW 95
8.1 DRIVERS 97
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 97
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 97
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 97
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 98
8.2 RESTRAINTS 98
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 98
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 99
8.3 OPPORTUNITIES 99
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 99
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 100
8.4 CHALLENGES 100
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 100
8.4.2 COMPLEX LABORATORY PROCESSES 101
9 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 102
9.1 OVERVIEW 103
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 106
9.2.1 GLUCOSE 107
9.2.1.1 GLUCOSE CHALLENGE TEST 107
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 107
9.2.2 PROTHROMBIN 108
9.2.3 METABOLIC PANEL 108
9.2.3.1 BASIC 108
9.2.3.2 COMPREHENSIVE 108
9.2.4 LIPID PANEL 108
9.2.5 LIVER PANEL 108
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 109
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 109
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 109
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 109
9.2.6 THYROID STIMULATING HORMONE 109
9.2.7 URINALYSIS 109
9.2.7.1 RED BLOOD CELL URINE TEST 110
9.2.7.2 GLUCOSE URINE TEST 110
9.2.7.3 PROTEIN URINE TEST 110
9.2.7.4 URINE PH LEVEL 110
9.2.7.5 KETONES URINE TEST 110
9.2.7.6 BILIBURIN URINE TEST 110
9.2.7.7 URINE SPECIFIC GRAVITY TEST 111
9.2.8 OTHERS 111
9.3 CRITICAL CARE 111
9.3.1 CARBOXYHAEMOGLOBIN TEST 112
9.3.2 PH TEST 112
9.3.3 POTASSIUM TEST 112
9.3.4 SODIUM TEST 112
9.3.5 METHEMOGLOBIN TEST 112
9.3.6 LACTATE TEST 112
9.3.7 OTHERS 113
9.4 HAEMATOLOGY 113
9.4.1 COMPLETE BLOOD COUNT (CBC) 114
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 114
9.4.1.2 RED BLOOD CELL COUNT (RBC) 114
9.4.2 PLATELET COUNT 114
9.4.3 BLOOD PROTEIN TESTING 115
9.4.4 OTHERS 115
9.5 MOLECULAR DIAGNOSTIC 115
9.5.1 SAMPLE TYPE 116
9.5.1.1 BLOOD 116
9.5.1.2 URINE 116
9.5.1.3 TISSUE 116
9.5.1.4 CEREBROSPINAL FLUID (CSF) 116
9.5.1.5 OTHERS 116
9.5.2 THERAPEUTIC AREA 116
9.5.2.1 INFECTIONS 117
9.5.2.2 GENETIC DISORDERS 117
9.5.2.3 ONCOLOGY/CANCER 117
9.5.2.4 AUTOIMMUNE DISEASE 117
9.5.2.5 UROLOGY 117
9.5.2.6 GYNECOLOGY 117
9.5.2.7 OTHERS 117
9.5.3 TECHNOLOGY 118
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 118
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 118
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 118
9.5.3.4 SANGER SEQUENCING 118
9.5.3.5 MICROARRAYS 118
9.5.3.6 MASS SPECTROMETRY 119
9.5.3.7 ISOTHERMAL AMPLIFICATION 119
9.5.4 END USER 119
9.5.4.1 HOSPITAL-BASED LABS 119
9.5.4.2 STAND-ALONE LABS 119
9.5.4.3 DIAGNOSTIC CHAINS 119
9.5.4.4 ACADEMIC INSTITUTES 120
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 120
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 120
9.5.4.7 OTHERS 120
9.6 MICROBIOLOGY 120
9.6.1 MICROSCOPY 121
9.6.2 CULTURE 121
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 121
9.6.4 OTHERS 121
9.7 OTHER TEST 122
9.7.1 DRUGS OF ABUSE TESTING 123
9.7.2 HEPATITIS 123
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 123
9.7.4 MALARIA 123
9.7.5 TUBERCULOSIS 123
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 123
9.7.7 OTHERS 124
10 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 125
10.1 OVERVIEW 126
10.2 CONSUMABLES 129
10.2.1 PANELS 129
10.2.2 REAGENT AND KITS 130
10.2.3 OTHERS 130
10.3 ANALYZERS AND INSTRUMENTS 130
10.3.1 FULLY-AUTOMATED INSTRUMENTS 131
10.3.2 SEMI-AUTOMATED INSTRUMENTS 131
10.3.3 OTHERS 131
10.4 ACCESSORIES 131
11 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 133
11.1 OVERVIEW 134
11.2 BLOOD 137
11.3 URINE 137
11.4 TISSUE 138
11.5 CEREBROSPINAL FLUID (CSF) 138
11.6 OTHERS 139
12 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 141
12.1 OVERVIEW 142
12.2 INFECTIONS 145
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 146
12.2.2 CLOSTRIDIUM DIFFICILE 146
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 146
12.2.4 CARBAPENEM-RESISTANT BACTERIA 146
12.2.5 FLU 146
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 147
12.2.7 CANDIDA 147
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 147
12.2.9 MENINGITIS 147
12.2.10 GASTROINTESTINAL PANEL TESTING 147
12.2.11 CHLAMYDIA 147
12.2.12 GONORRHEA 147
12.2.13 HIV 147
12.2.14 HEPATITIS B 147
12.2.15 HEPATITIS C 147
12.2.16 OTHER INFECTIOUS DISEASES 147
12.3 GENETIC DISORDERS 148
12.3.1 NEW BORN SCREENING 148
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 149
12.3.3 OTHER GENETIC TESTING 149
12.4 ONCOLOGY/CANCER 149
12.4.1 BREAST CANCER 150
12.4.2 PROSTATE CANCER 150
12.4.3 COLORECTAL CANCER 150
12.4.4 CERVICAL CANCER 150
12.4.5 KIDNEY CANCER 150
12.4.6 LIVER CANCER 150
12.4.7 BLOOD CANCER 150
12.4.8 LUNG CANCER 151
12.4.9 OTHER CANCER 151
12.5 AUTOIMMUNE DISEASE 151
12.6 UROLOGY 151
12.7 GYNECOLOGY 152
12.8 OTHERS 153
13 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 154
13.1 OVERVIEW 155
13.2 MALE 158
13.3 FEMALE 158
14 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 160
14.1 OVERVIEW 161
14.2 GERIATRICS 164
14.3 ADULT 164
14.4 PEDIATRICS 165
15 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 166
15.1 OVERVIEW 167
15.2 HOSPITAL-BASED LABS 170
15.3 STAND –ALONE LABS 170
15.4 DIAGNOSTIC CHAINS 171
15.5 ACADEMIC INSTITUTES 172
15.6 CLINICAL RESEARCH ORGANISTAION 172
15.7 SPECIALTY DIAGNOSTIC 173
15.8 OTHERS 174
16 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 175
16.1 OVERVIEW 176
16.2 DIRECT TENDER 179
16.3 RETAIL SALES 179
16.4 THIRD PARTY DISTRIBUTORS 180
16.5 OTHERS 181
17 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 182
17.1 NORTH AMERICA 183
17.1.1 U.S. 198
17.1.2 CANADA 207
17.1.3 MEXICO 216
18 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 225
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 225
19 COMPANY PROFILES 226
19.1 F. HOFFMANN-LA ROCHE LTD. 226
19.1.1 COMPANY SNAPSHOT 226
19.1.2 REVENUE ANALYSIS 226
19.1.3 COMPANY SHARE ANALYSIS 227
19.1.4 PRODUCT PORTFOLIO 227
19.1.5 RECENT DEVELOPMENT 227
19.2 BIOMÉRIEUX 228
19.2.1 COMPANY SNAPSHOT 228
19.2.2 REVENUE ANALYSIS 228
19.2.3 COMPANY SHARE ANALYSIS 229
19.2.4 PRODUCT PORTFOLIO 229
19.2.5 RECENT DEVELOPMENTS 229
19.3 SYSMEX CORPORATION 230
19.3.1 COMPANY SNAPSHOT 230
19.3.2 REVENUE ANALYSIS 230
19.3.3 COMPANY SHARE ANALYSIS 231
19.3.4 PRODUCT PORTFOLIO 231
19.3.5 RECENT DEVELOPMENT 231
19.4 BIOMERICA. 232
19.4.1 COMPANY SNAPSHOT 232
19.4.2 REVENUE ANALYSIS 232
19.4.3 COMPANY SHARE ANALYSIS 233
19.4.4 PRODUCT PORTFOLIO 233
19.4.5 RECENT DEVELOPMENT 233
19.5 BIO-RAD LABORATORIES, INC 234
19.5.1 COMPANY SNAPSHOT 234
19.5.2 REVENUE ANALYSIS 234
19.5.3 COMPANY SHARE ANALYSIS 235
19.5.4 PRODUCT PORTFOLIO 235
19.5.5 RECENT DEVELOPMENT 235
19.6 23ANDME, INC. 236
19.6.1 COMPANY SNAPSHOT 236
19.6.2 REVENUE ANALYSIS 236
19.6.3 PRODUCT PORTFOLIO 237
19.6.4 RECENT DEVELOPMENTS 237

　

ページTOPに戻る


　

Summary

The North America Laboratory-Developed Tests (LDTs) Market is expected to reach USD 17,680.85 Million by 2030 from USD 6,901.04 Million in 2022, growing at a CAGR of 12.5% during the forecast period of 2023 to 2030.

Market Segmentation
North America Laboratory-Developed Tests (LDTs) Market, By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics, Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others), Country (U.S., Canada, Mexico) - Industry Trends and Forecast to 2030

Overview of North America Laboratory-Developed Tests (LDTs) Market Dynamics

Drivers

• Increasing demand for personalized medicines
• Advancements in molecular diagnostics

Restraint

• Stringent quality control and standardization for LDTs
Opportunity

• Increasing demand for precision medicine and targeted therapy
Market Players
Some of the major market players operating in the North America Laboratory-Developed Tests (LDTs) market are:
• F. Hoffmann-La Roche Ltd
• bioMérieux, Inc.
• Sysmex Corporation
• Biomerica, Inc.
• Bio-Rad Laboratories, Inc.
• Abbott
• Siemens Medical Solutions USA, Inc.
• Quest Diagnostics Incorporated
• QIAGEN
• Eurofins Scientific
• Biodesix.
• Hologic, Inc.
• Guardant Health
• OPKO Health, Inc.
• BD
• Beckman Coulter, Inc.
• NeoGenomics Laboratories.
• Seegene Inc.
• Ambry Genetics
• BGI
• 23andMe, Inc.
• Admera Health
• Agendia



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 65
1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF THE NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 65
1.4 CURRENCY AND PRICING 67
1.5 LIMITATIONS 67
1.6 MARKETS COVERED 67
2 MARKET SEGMENTATION 72
2.1 MARKETS COVERED 72
2.2 GEOGRAPHICAL SCOPE 73
2.3 YEARS CONSIDERED FOR THE STUDY 74
2.4 DBMR TRIPOD DATA VALIDATION MODEL 75
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.6 MULTIVARIATE MODELLING 79
2.7 TEST TYPE SEGMENT LIFELINE CURVE 79
2.8 MARKET END USER COVERAGE GRID 80
2.9 DBMR MARKET POSITION GRID 81
2.10 VENDOR SHARE ANALYSIS 82
2.11 SECONDARY SOURCES 83
2.12 ASSUMPTIONS 83
3 EXECUTIVE SUMMARY 84
4 PREMIUM INSIGHTS 87
4.1 PESTEL ANALYSIS 88
4.2 PORTER'S FIVE FORCES MODEL 89
5 INDUSTRY INSIGHTS 90
6 NUMBER OF LABS 92
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 92
6.2 NUMBER OF LABS IN EUROPE 92
7 REGULATIONS OF THE NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 94
7.1 U.S. 94
8 MARKET OVERVIEW 95
8.1 DRIVERS 97
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 97
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 97
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 97
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 98
8.2 RESTRAINTS 98
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 98
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 99
8.3 OPPORTUNITIES 99
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 99
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 100
8.4 CHALLENGES 100
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 100
8.4.2 COMPLEX LABORATORY PROCESSES 101
9 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 102
9.1 OVERVIEW 103
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 106
9.2.1 GLUCOSE 107
9.2.1.1 GLUCOSE CHALLENGE TEST 107
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 107
9.2.2 PROTHROMBIN 108
9.2.3 METABOLIC PANEL 108
9.2.3.1 BASIC 108
9.2.3.2 COMPREHENSIVE 108
9.2.4 LIPID PANEL 108
9.2.5 LIVER PANEL 108
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 109
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 109
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 109
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 109
9.2.6 THYROID STIMULATING HORMONE 109
9.2.7 URINALYSIS 109
9.2.7.1 RED BLOOD CELL URINE TEST 110
9.2.7.2 GLUCOSE URINE TEST 110
9.2.7.3 PROTEIN URINE TEST 110
9.2.7.4 URINE PH LEVEL 110
9.2.7.5 KETONES URINE TEST 110
9.2.7.6 BILIBURIN URINE TEST 110
9.2.7.7 URINE SPECIFIC GRAVITY TEST 111
9.2.8 OTHERS 111
9.3 CRITICAL CARE 111
9.3.1 CARBOXYHAEMOGLOBIN TEST 112
9.3.2 PH TEST 112
9.3.3 POTASSIUM TEST 112
9.3.4 SODIUM TEST 112
9.3.5 METHEMOGLOBIN TEST 112
9.3.6 LACTATE TEST 112
9.3.7 OTHERS 113
9.4 HAEMATOLOGY 113
9.4.1 COMPLETE BLOOD COUNT (CBC) 114
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 114
9.4.1.2 RED BLOOD CELL COUNT (RBC) 114
9.4.2 PLATELET COUNT 114
9.4.3 BLOOD PROTEIN TESTING 115
9.4.4 OTHERS 115
9.5 MOLECULAR DIAGNOSTIC 115
9.5.1 SAMPLE TYPE 116
9.5.1.1 BLOOD 116
9.5.1.2 URINE 116
9.5.1.3 TISSUE 116
9.5.1.4 CEREBROSPINAL FLUID (CSF) 116
9.5.1.5 OTHERS 116
9.5.2 THERAPEUTIC AREA 116
9.5.2.1 INFECTIONS 117
9.5.2.2 GENETIC DISORDERS 117
9.5.2.3 ONCOLOGY/CANCER 117
9.5.2.4 AUTOIMMUNE DISEASE 117
9.5.2.5 UROLOGY 117
9.5.2.6 GYNECOLOGY 117
9.5.2.7 OTHERS 117
9.5.3 TECHNOLOGY 118
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 118
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 118
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 118
9.5.3.4 SANGER SEQUENCING 118
9.5.3.5 MICROARRAYS 118
9.5.3.6 MASS SPECTROMETRY 119
9.5.3.7 ISOTHERMAL AMPLIFICATION 119
9.5.4 END USER 119
9.5.4.1 HOSPITAL-BASED LABS 119
9.5.4.2 STAND-ALONE LABS 119
9.5.4.3 DIAGNOSTIC CHAINS 119
9.5.4.4 ACADEMIC INSTITUTES 120
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 120
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 120
9.5.4.7 OTHERS 120
9.6 MICROBIOLOGY 120
9.6.1 MICROSCOPY 121
9.6.2 CULTURE 121
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 121
9.6.4 OTHERS 121
9.7 OTHER TEST 122
9.7.1 DRUGS OF ABUSE TESTING 123
9.7.2 HEPATITIS 123
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 123
9.7.4 MALARIA 123
9.7.5 TUBERCULOSIS 123
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 123
9.7.7 OTHERS 124
10 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 125
10.1 OVERVIEW 126
10.2 CONSUMABLES 129
10.2.1 PANELS 129
10.2.2 REAGENT AND KITS 130
10.2.3 OTHERS 130
10.3 ANALYZERS AND INSTRUMENTS 130
10.3.1 FULLY-AUTOMATED INSTRUMENTS 131
10.3.2 SEMI-AUTOMATED INSTRUMENTS 131
10.3.3 OTHERS 131
10.4 ACCESSORIES 131
11 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 133
11.1 OVERVIEW 134
11.2 BLOOD 137
11.3 URINE 137
11.4 TISSUE 138
11.5 CEREBROSPINAL FLUID (CSF) 138
11.6 OTHERS 139
12 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 141
12.1 OVERVIEW 142
12.2 INFECTIONS 145
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 146
12.2.2 CLOSTRIDIUM DIFFICILE 146
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 146
12.2.4 CARBAPENEM-RESISTANT BACTERIA 146
12.2.5 FLU 146
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 147
12.2.7 CANDIDA 147
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 147
12.2.9 MENINGITIS 147
12.2.10 GASTROINTESTINAL PANEL TESTING 147
12.2.11 CHLAMYDIA 147
12.2.12 GONORRHEA 147
12.2.13 HIV 147
12.2.14 HEPATITIS B 147
12.2.15 HEPATITIS C 147
12.2.16 OTHER INFECTIOUS DISEASES 147
12.3 GENETIC DISORDERS 148
12.3.1 NEW BORN SCREENING 148
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 149
12.3.3 OTHER GENETIC TESTING 149
12.4 ONCOLOGY/CANCER 149
12.4.1 BREAST CANCER 150
12.4.2 PROSTATE CANCER 150
12.4.3 COLORECTAL CANCER 150
12.4.4 CERVICAL CANCER 150
12.4.5 KIDNEY CANCER 150
12.4.6 LIVER CANCER 150
12.4.7 BLOOD CANCER 150
12.4.8 LUNG CANCER 151
12.4.9 OTHER CANCER 151
12.5 AUTOIMMUNE DISEASE 151
12.6 UROLOGY 151
12.7 GYNECOLOGY 152
12.8 OTHERS 153
13 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 154
13.1 OVERVIEW 155
13.2 MALE 158
13.3 FEMALE 158
14 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 160
14.1 OVERVIEW 161
14.2 GERIATRICS 164
14.3 ADULT 164
14.4 PEDIATRICS 165
15 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 166
15.1 OVERVIEW 167
15.2 HOSPITAL-BASED LABS 170
15.3 STAND –ALONE LABS 170
15.4 DIAGNOSTIC CHAINS 171
15.5 ACADEMIC INSTITUTES 172
15.6 CLINICAL RESEARCH ORGANISTAION 172
15.7 SPECIALTY DIAGNOSTIC 173
15.8 OTHERS 174
16 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 175
16.1 OVERVIEW 176
16.2 DIRECT TENDER 179
16.3 RETAIL SALES 179
16.4 THIRD PARTY DISTRIBUTORS 180
16.5 OTHERS 181
17 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 182
17.1 NORTH AMERICA 183
17.1.1 U.S. 198
17.1.2 CANADA 207
17.1.3 MEXICO 216
18 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 225
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 225
19 COMPANY PROFILES 226
19.1 F. HOFFMANN-LA ROCHE LTD. 226
19.1.1 COMPANY SNAPSHOT 226
19.1.2 REVENUE ANALYSIS 226
19.1.3 COMPANY SHARE ANALYSIS 227
19.1.4 PRODUCT PORTFOLIO 227
19.1.5 RECENT DEVELOPMENT 227
19.2 BIOMÉRIEUX 228
19.2.1 COMPANY SNAPSHOT 228
19.2.2 REVENUE ANALYSIS 228
19.2.3 COMPANY SHARE ANALYSIS 229
19.2.4 PRODUCT PORTFOLIO 229
19.2.5 RECENT DEVELOPMENTS 229
19.3 SYSMEX CORPORATION 230
19.3.1 COMPANY SNAPSHOT 230
19.3.2 REVENUE ANALYSIS 230
19.3.3 COMPANY SHARE ANALYSIS 231
19.3.4 PRODUCT PORTFOLIO 231
19.3.5 RECENT DEVELOPMENT 231
19.4 BIOMERICA. 232
19.4.1 COMPANY SNAPSHOT 232
19.4.2 REVENUE ANALYSIS 232
19.4.3 COMPANY SHARE ANALYSIS 233
19.4.4 PRODUCT PORTFOLIO 233
19.4.5 RECENT DEVELOPMENT 233
19.5 BIO-RAD LABORATORIES, INC 234
19.5.1 COMPANY SNAPSHOT 234
19.5.2 REVENUE ANALYSIS 234
19.5.3 COMPANY SHARE ANALYSIS 235
19.5.4 PRODUCT PORTFOLIO 235
19.5.5 RECENT DEVELOPMENT 235
19.6 23ANDME, INC. 236
19.6.1 COMPANY SNAPSHOT 236
19.6.2 REVENUE ANALYSIS 236
19.6.3 PRODUCT PORTFOLIO 237
19.6.4 RECENT DEVELOPMENTS 237

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

Data Bridge Market Research 社の最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/20　10:26

143.76 円

160.81 円

193.57 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.